J&J Could Get Japanese Approval For Ripivirine Within Four Months
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson subsidiary Janssen Pharma K.K. announced Feb. 3 a new drug approval application for antiretroviral Edurant (ripivirine) in Japan.